New trial
Phase 2/3 Zanzalintinib Trial: cMet/VEGFR inhibitor in Neuroendocrine Tumors
- Trial ID
- NCT06943755 on ClinicalTrials.gov
- Cancer type
- Neuroendocrine Tumor
- Stage of research
- Exploratory
- Published in
- New in Oncology - July 3, 2025
This multicenter, randomized open-label study sponsored by Exelixis compares daily oral zanzalintinib to everolimus in patients with previously treated, unresectable locally advanced or metastatic neuroendocrine tumors (Grade 1-3) of pancreatic or extra-pancreatic origin. The trial explores the effectiveness of a cMet/VEGFR inhibitor in a progressing population.
More in neuroendocrine and adrenal tumors
-
Trial result · Oct 15, 2026 · NCT00107289
Single ¹³¹I-MIBG (NET-targeted radiopharmaceutical) + single autologous stem cell rescue shows feasible engraftment but low response in resistant neuroblastoma -
Trial result · Aug 27, 2026 · NCT03972488
¹⁷⁷Lu-DOTATATE (SSTR-targeted PRRT) extends PFS ~14 months vs high-dose octreotide in 1L G2–G3 GEP-NETs -
New trial · Aug 27, 2026 · NCT07743138
Phase 2 ivonescimab PD-1×VEGF bispecific antibody in previously treated ACC/PPGL -
Trial result · Aug 6, 2026 · NCT03049189
[177Lu]Lu-edotreotide (SSTR2-targeted PRRT) beats everolimus on PFS in progressive GEP-NETs (COMPETE) -
New trial · Jul 16, 2026 · NCT07661420
Phase 1 211At‑MABG targeted alpha radiotherapy (NET/norepinephrine transporter–avid) in advanced NETs